ArticleACS applied materials & interfaces2025
Development of Iron Oxide Nanochains as a Sensitive Magnetic Particle Imaging Tracer for Cancer Detection.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From Magnetic Moment to Magnetic Particle Imaging: A Comprehensive Review on MPI Technology, Tracer Design and Biological Applications.Pharmaceutics · 2026Review
- Effect of clinically relevant iron oxide nanoparticles on macrophage polarization, tumor growth and tumor microenvironment modulation.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Nanoparticle retention enables non-invasive detection of metastases by magnetic particle imaging in murine breast cancer models.Theranostics · 2026Article
- Metal nanoparticles in cancer theranostics: from synthesis to tumor microenvironment-responsive applications.Drug delivery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The advancement of imaging technologies plays a crucial role in improving the diagnosis and monitoring of diseases, including cancer. This study introduces a new design of iron oxide-based nanoparticles specifically developed for magnetic particle imaging (MPI), aimed at tracking and diagnosing breast cancer more effectively. By precisely controlling the size, shape, and magnetic properties of these nanoparticles, we enhance the responsiveness of MPI, resulting in an increased signal. In our research, we established a novel synthetic route for fabricating iron oxide nanochains (FeONCs) characterized by their uniform shape and size, which contribute to high magnetic properties suitable for MPI applications. Initial results indicate these FeONCs exhibit superior magnetic properties compared to conventional spherical superparamagnetic iron oxide nanoparticles, nanocubes, and reported nanoworm-type structures. Magnetic relaxometry studies revealed that FeONCs provide higher sensitivity than the commonly used VivoTrax Synomag D50 and D70 in MPI. Further, the size and shape of FeONCs significantly influence cellular uptake. In vivo experiments using orthotopic breast cancer mouse models allow us to assess the biocompatibility and magnetic characteristics of the nanoparticles, confirming their imaging efficacy. Furthermore, by conjugating these nanoparticles with the RGD peptide, we enhance their ability to specifically target breast cancer, establishing them as promising tracers for in vivo MPI applications characterized by high sensitivity. Thus, our findings highlight that FeONCs significantly improve imaging quality, facilitating the early detection and accurate monitoring of breast cancer. This paves the way for innovative diagnostic strategies and personalized treatment options. Future research will focus on fine-tuning the surface chemistry of these nanoparticles to further enhance the targeting efficiency and optimization of their practice in clinical applications, particularly for MPI-based hyperthermia therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.